Clinical Trials Logo

Melanoma clinical trials

View clinical trials related to Melanoma.

Filter by:

NCT ID: NCT00020267 Completed - Breast Cancer Clinical Trials

Vaccine Therapy in Treating Patients With Metastatic Cancer

Start date: July 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic cancer that has not responded to previous therapy.

NCT ID: NCT00019994 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Start date: October 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic melanoma that has not responded to previous therapy.

NCT ID: NCT00019890 Completed - Stage IV Melanoma Clinical Trials

Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma

Start date: n/a
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating patients who have high-risk stage III or completely resected metastatic melanoma.

NCT ID: NCT00019734 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Start date: July 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy with and without interleukin-2 in treating patients who have metastatic melanoma that has not responded to previous treatment.

NCT ID: NCT00019721 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Start date: April 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining vaccine therapy with interleukin-2 may be an effective treatment for metastatic melanoma. PURPOSE: Phase II trial to compare the effectiveness of vaccine therapy with or without interleukin-2 in treating patients who have metastatic melanoma that has not responded to previous therapy.

NCT ID: NCT00019682 Completed - Recurrent Melanoma Clinical Trials

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

Start date: December 1999
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies aldesleukin with vaccine therapy to see how well it works compared to aldesleukin alone in treating patients with melanoma that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Aldesleukin may stimulate a person's white blood cells to kill melanoma cells. Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether combining aldesleukin with vaccine therapy is more effective than aldesleukin alone in treating melanoma.

NCT ID: NCT00019669 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Start date: October 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether combining melanoma vaccine with interleukin-2 is more effective than vaccine therapy alone in treating metastatic melanoma. PURPOSE: Phase II trial to compare the effectiveness of melanoma vaccine and interleukin-2 with that of melanoma vaccine alone in treating patients who have metastatic melanoma that has not responded to previous treatment.

NCT ID: NCT00019487 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Start date: November 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines made from a person's white blood cells may make the body build an immune response and kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic melanoma that has not responded to previous therapy.

NCT ID: NCT00019448 Completed - Stage IV Melanoma Clinical Trials

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Start date: September 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. Combining vaccine therapy and interleukin-2 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy with or without interleukin-2 in treating patients with metastatic melanoma that has not responded to previous treatment.

NCT ID: NCT00019396 Completed - Stage IV Melanoma Clinical Trials

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Start date: February 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: The drug flt3L may stimulate a person's immune system and help to kill tumor cells. Vaccines made from melanoma cells may make the body build an immune response to and kill their tumor cells. PURPOSE: Phase II trial to study the effectiveness of flt3L with or without vaccine therapy in treating patients with metastatic melanoma or renal cell cancer.